Piramal Pharma Solutions Unveils Cutting-Edge Payload-Linker Suite in Michigan
Piramal Pharma Solutions launches a new payload-linker manufacturing suite at its Michigan facility, marking a vital part of a $90 million U.S. manufacturing expansion plan. This development aims to enhance their capacity for complex drug production, reinforcing their commitment to innovative U.S.-based solutions.
Piramal Pharma Solutions, a renowned global Contract Development and Manufacturing Organization (CDMO), has inaugurated a state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan drug substance facility. This addition is a critical component of a larger $90 million investment to bolster U.S. manufacturing capabilities, announced previously by the company.
Aside from the payload-linker suite, the expansion plan includes new technology and enhanced commercial-scale manufacturing capabilities at its sterile injectables facility in Lexington, Kentucky. These advancements underscore the company's dedication to delivering complex and innovative therapies swiftly and reliably to patients on a global scale.
Piramal Pharma Solutions, with over 60 years in drug substance development and manufacturing, harnesses its expertise at Riverview, which serves as a dedicated payload-linker supplier. The new suite, equipped with advanced technologies, strengthens the ADCelerate™ platform, positioning the company to meet increased demand for ADCs and related therapies.
(With inputs from agencies.)
Google News